Published finding — does the expert body still believe it?
Icosapent ethyl 4 g daily is associated with a significantly higher rate of hospitalization for atrial fibrillation or flutter (3.1% vs. 2.1%) compared to placebo in statin-treated patients with elevated triglycerides.
TL;DR · AI-generated
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than amongThose who received placebo.
Author-implied confidence
85%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
93% → 93% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
· openalex W2899669642 · s2 eaa96eb4
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1419
Icosapent ethyl 4 g daily significantly reduces cardiovascular mortality (4.3% vs. 5.2%; HR 0.80) compared to placebo in statin-treated patients with elevated triglycerides.
0.1447
Icosapent ethyl 4 g daily reduces the key secondary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke by 26% (HR 0.74) compared to placebo in statin-treated patients with elevated triglycerides.
0.1469
Icosapent ethyl 4 g daily reduces the composite primary endpoint of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina by 25% (HR 0.75) compared to placebo in statin-treated patients with elevated triglycerides over a median 4.9-year follow-up.
0.2165
The cardiovascular benefit of icosapent ethyl will not be replicated by other omega-3 fatty acid formulations containing DHA in addition to EPA at comparable doses.
0.2312
The cardiovascular benefit of icosapent ethyl observed in REDUCE-IT is attributable to mechanisms beyond triglyceride lowering alone, given the magnitude of risk reduction exceeds what triglyceride reduction alone would predict.
0.2539
Evolocumab treatment in ASCVD patients on statins was not associated with a significant increase in new-onset diabetes or neurocognitive adverse events compared with placebo.